7 completed, 2 recruiting, 1 active not recruiting. 5 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
Follow LDP-02: new trials by email Literature Review of LDP-02 trials Research Report on LDP-02
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 800 | 2021-02-21 | 2026-07-15 |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Infliximab, Vedolizumab - Colitis, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2020-07-09 | 2026-07-15 |
| Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab Vedolizumab, Placebo, Hepatitis B vaccine - Inflammatory Bowel Disease | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 127 | 2011-09-01 | 2014-07-21 |
| Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease vedolizumab, Placebo - Crohn's Disease | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 416 | 2010-11-01 | 2014-07-21 |
| Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis vedolizumab, Placebo - Ulcerative Colitis | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 895 | 2009-01-01 | 2014-07-18 |
| Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease vedolizumab, Placebo - Crohn's Disease | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 1116 | 2008-12-01 | 2014-07-21 |
| Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease vedolizumab - Ulcerative Colitis, Crohn's Disease | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 72 | 2007-12-01 | 2014-07-18 |
| Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis Vedolizumab, Placebo - Ulcerative Colitis | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 47 | 2007-05-01 | 2014-07-18 |
| Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients LDP-02, Placebo - Crohn's Disease | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 185 | 2000-02-01 | 2008-04-09 |
Crohn Disease (4) · Colitis, Ulcerative (3) · Carcinoma, Non-Small-Cell Lung (2) · Colitis (2) · Urogenital Neoplasms (2) · Graft vs Host Disease (1) · Inflammatory Bowel Diseases (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lung Neoplasms (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Millennium Pharmaceuticals, Inc. (7) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1)
United States (6) · Canada (4) · Puerto Rico (2) · United Kingdom (1)
Yinghong Wang (2) · Monzr M. Al Malki (1)
PMID 26893500, PMID 25996351, PMID 29857145, PMID 30203005, PMID 30615117, PMID 32635680, PMID 33200296, PMID 18829392, PMID 23964932, PMID 23964933, PMID 24763133, PMID 24859203, PMID 27639327, PMID 27802155, PMID 29471381, PMID 30285104, PMID 30365009, PMID 32062041, PMID 32606883, PMID 35934286
2008 (2), 2009 (1), P30CA033572 (1)